Download PDF
Intensivmedizin up2date 2007; 3(1): 21-40
DOI: 10.1055/s-2006-945183
Allgemeine Prinzipien der Intensivmedizin

© Georg Thieme Verlag KG Stuttgart · New York

Antimykotische Therapie in der Intensivmedizin

Christoph  Lichtenstern, Heinrich  K.  Geiss, Bernd  W.  Böttiger, Markus  A.  Weigand
Further Information

Publication History

Publication Date:
21 February 2007 (online)

Also available at
    Permissions and Reprints All articles of this category

Kernaussagen

Obwohl die invasive Candidiasis ein verbreitetes Problem ist, ist eine routinemäßige antimykotische Prophylaxe beim nicht-neutropenen oder immunsupprimierten Patienten bisher noch nicht indiziert, da große multizentrische Studien dazu bislang fehlen. Außerdem ist die epidemiologische Entwicklung hin zu resistenten Candida spp. zu beachten. Darüber hinaus sollte eine empirische bzw. präemptive Therapie nach einer validierten Risikoabschätzung wertvoller sein als die Prophylaxe. Die neu auftretenden komplexen Pilzinfektionen der kritisch kranken Patienten auf Intensivstationen - unabhängig ob durch Hefe- oder Schimmelpilze verursacht - machen evidenzbasierte Therapiestrategien notwendig (Abb. [2] und [3]). Dabei sollte es das Ziel sein, die Überlebensrate der Intensivpatienten deutlich zu verbessern.

Literatur

  • 1 Martin G S, Mannino D M, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000.  N Engl J Med. 2003;  348 1546-1554
    CrossrefPubMedGoogle Scholar
  • 2 Blumberg H M, Jarvis W R, Soucie J M. et al . Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey.  Clin Infect Dis. 2001;  33 177-186
    CrossrefPubMedGoogle Scholar
  • 3 Petri M G, Konig J, Moecke H P. et al . Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research.  Intensive Care Med. 1997;  23 317-325
    CrossrefPubMedGoogle Scholar
  • 4 Vincent J L, Anaissie E, Bruining H. et al . Epidemiology, diagnosis and treatment of systemic Candida infection in surgical patients under intensive care.  Intensive Care Med. 1998;  24 206-216
    CrossrefPubMedGoogle Scholar
  • 5 Vincent J L, Sakr Y, Sprung C L. et al . Sepsis in European intensive care units: results of the SOAP study.  Crit Care Med. 2006;  34 344-353
    CrossrefPubMedGoogle Scholar
  • 6 Pfaller M A, Jones R N, Doern G V. et al . International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group.  J Clin Microbiol. 1998;  36 1886-1889
    PubMedGoogle Scholar
  • 7 Pfaller M, Pappas P, Wingard J. Invasive Fungal Pathogens: Current Epidemiological Trends.  Clin Infect Dis. 2006;  43 S3-S14
    CrossrefPubMedGoogle Scholar
  • 8 Mora-Duarte J, Betts R, Rotstein C. et al . Comparison of caspofungin and Amphotericin B for invasive candidiasis.  N Engl J Med. 2002;  347 2020-2029
    CrossrefPubMedGoogle Scholar
  • 9 Morrell M, Fraser V J, Kollef M H. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.  Antimicrob Agents Chemother. 2005;  49 3640-3645
    CrossrefPubMedGoogle Scholar
  • 10 Ostrosky-Zeichner L, Pappas P. Invasive candidiasis in the intensive care unit.  Crit Care Med. 2006;  34 857-863
    CrossrefPubMedGoogle Scholar
  • 11 Munoz P, Burillo A, Bouza E. Criteria used when initiating antifungal therapy against Candida spp. in the intensive care unit.  Int J Antimicrob Agents. 2000;  15 83-90
    PubMedGoogle Scholar
  • 12 Kam A P, Xu J. Diversity of commensal yeasts within and among healthy hosts.  Diagn Microbiol Infect Dis. 2002;  43 19-28
    CrossrefPubMedGoogle Scholar
  • 13 Solomkin J S, Mazuski J E, Baron E J. et al . Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections.  Clin Infect Dis. 2003;  37 997-1005
    CrossrefPubMedGoogle Scholar
  • 14 Alexander B, Pfaller M A. Contemporary Tools for the Diagnosis and Management of Invasive Mycoses.  Clin Infect Dis. 2006;  43 S15-S23
    CrossrefPubMedGoogle Scholar
  • 15 Hope W W, Walsh T J, Denning D W. Laboratory diagnosis of invasive aspergillosis.  Lancet Infect Dis. 2005;  5 609-622
    CrossrefPubMedGoogle Scholar
  • 16 Odabasi Z, Mattiuzzi G, Estey E. et al . Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome.  Clin Infect Dis. 2004;  39 199-205
    CrossrefPubMedGoogle Scholar
  • 17 Ostrosky-Zeichner L, Alexander B D, Kett D H. et al . Multicenter clinical evaluation of the (1 → 3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans.  Clin Infect Dis. 2005;  41 654-659
    CrossrefPubMedGoogle Scholar
  • 18 Dodds A shley, Lewis R, Lewis J S. et al . Pharmacology of Systemic Antifungal Agents.  Clinical Infectious Diseases. 2006;  43 S28-S39
    CrossrefPubMedGoogle Scholar
  • 19 Bates D W, Su L, Yu D T. et al . Mortality and costs of acute renal failure associated with Amphotericin B therapy.  Clin Infect Dis. 2001;  32 686-693
    PubMedGoogle Scholar
  • 20 Ostrosky-Zeichner L, Marr K A, Rex J H, Cohen S H. Amphotericin B: time for a new „gold standard”.  Clin Infect Dis. 2003;  37 415-425
    CrossrefPubMedGoogle Scholar
  • 21 Maschmeyer G, Ruhnke M. Update on antifungal treatment of invasive Candida and Aspergillus infections.  Mycoses. 2004;  47 263-276
    CrossrefPubMedGoogle Scholar
  • 22 Bates D W, Yu D T. Clinical impact of drug-drug interactions with systemic azole antifungals.  Drugs Today (Barc). 2003;  39 801-813
    CrossrefPubMedGoogle Scholar
  • 23 Charlier C, Hart E, Lefort A. et al . Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?.  J Antimicrob Chemother. 2006;  57 384-410
    CrossrefPubMedGoogle Scholar
  • 24 Pappas P G, Rex J H, Sobel J D. et al . Guidelines for treatment of candidiasis.  Clin Infect Dis. 2004;  38 161-189
    CrossrefPubMedGoogle Scholar
  • 25 Boyd A E, Modi S, Howard S J. et al . Adverse reactions to voriconazole.  Clin Infect Dis. 2004;  39 1241-1244
    CrossrefPubMedGoogle Scholar
  • 26 FDA ADAC .Briefing Document for Voriconazole (Oral and Intravenous Formulations). 2001
    Google Scholar
  • 27 Raad I, Chapman S, Bradsher R. Posaconazole (POS) Salvage Therapy for Invasive Fungal Infections (IFI).  ICAAC. 2004;  Abstract
    PubMedGoogle Scholar
  • 28 Denning D W. Echinocandin antifungal drugs.  Lancet. 2003;  362 1142-1151
    CrossrefPubMedGoogle Scholar
  • 29 Goodman J L, Winston D J, Greenfield R A. et al . A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation.  N Engl J Med. 1992;  326 845-851
    PubMedGoogle Scholar
  • 30 Shorr A F, Chung K, Jackson W L. et al . Fluconazole prophylaxis in critically ill surgical patients: A meta-analysis.  Crit Care Med. 2005;  33 1928-1935
    CrossrefPubMedGoogle Scholar
  • 31 Pelz R K, Hendrix C W, Swoboda S M. et al . Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients.  Ann Surg. 2001;  233 542-548
    CrossrefPubMedGoogle Scholar
  • 32 Playford E G, Webster A C, Sorrell T C, Craig J C. Antifungal agents for preventing fungal infections in non-neutropenic critically ill and surgical patients: systematic review and meta-analysis of randomized clinical trials.  J Antimicrob Chemother. 2006;  57 628-638
    CrossrefPubMedGoogle Scholar
  • 33 Winston D J, Pakrasi A, Busuttil R W. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial.  Ann Intern Med. 1999;  131 729-737
    PubMedGoogle Scholar
  • 34 Klastersky J. Antifungal therapy in patients with fever and neutropenia-more rational and less empirical?.  N Engl J Med. 2004;  351 1445-1447
    CrossrefPubMedGoogle Scholar
  • 35 Pittet D, Monod M, Suter P M. et al . Candida colonization and subsequent infections in critically ill surgical patients.  Ann Surg. 1994;  220 751-758
    CrossrefPubMedGoogle Scholar
  • 36 Walsh T J, Teppler H, Donowitz G R. et al . Caspofungin versus liposomal Amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.  N Engl J Med. 2004;  351 1391-1402
    CrossrefPubMedGoogle Scholar
  • 37 Walsh T J, Pappas P, Winston D J. et al . Voriconazole compared with liposomal Amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.  N Engl J Med. 2002;  346 225-234
    CrossrefPubMedGoogle Scholar
  • 38 Ostrosky-Zeichner L, Oude L ashof, Kullberg B J, Rex J H. Voriconazole salvage treatment of invasive candidiasis.  Eur J Clin Microbiol Infect Dis. 2003;  22 651-655
    CrossrefPubMedGoogle Scholar
  • 39 Kullberg B J, Sobel J D, Ruhnke M. et al . Voriconazole versus a regimen of Amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.  Lancet. 2005;  366 1435-1442
    CrossrefPubMedGoogle Scholar
  • 40 Rex J H, Pappas P G, Karchmer A W. et al . A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus Amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.  Clin Infect Dis. 2003;  36 1221-1228
    CrossrefPubMedGoogle Scholar
  • 41 Arathoon E G, Gotuzzo E, Noriega L M. et al . Randomized, double-blind, multicenter study of caspofungin versus Amphotericin B for treatment of oropharyngeal and esophageal candidiases.  Antimicrob Agents Chemother. 2002;  46 451-457
    CrossrefPubMedGoogle Scholar
  • 42 Villanueva A, Gotuzzo E, Arathoon E G. et al . A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis.  Am J Med. 2002;  113 294-299
    CrossrefPubMedGoogle Scholar
  • 43 Ally R, Schurmann D, Kreisel W. et al . A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients.  Clin Infect Dis. 2001;  33 1447-1454
    CrossrefPubMedGoogle Scholar
  • 44 Sandven P, Qvist H, Skovlund E, Giercksky K E. Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations.  Crit Care Med. 2002;  30 541-547
    CrossrefPubMedGoogle Scholar
  • 45 Stevens D A, Kan V L, Judson M A. et al . Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America.  Clin Infect Dis. 2000;  30 696-709
    CrossrefPubMedGoogle Scholar
  • 46 Perfect J R, Marr K A, Walsh T J. et al . Voriconazole treatment for less-common, emerging, or refractory fungal infections.  Clin Infect Dis. 2003;  36 1122-1131
    CrossrefPubMedGoogle Scholar
  • 47 Maertens J, Raad I, Petrikkos G. et al . Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.  Clin Infect Dis. 2004;  39 1563-1571
    CrossrefPubMedGoogle Scholar
  • 48 Herbrecht R, Denning D W, Patterson T F. et al . Voriconazole versus Amphotericin B for primary therapy of invasive aspergillosis.  N Engl J Med. 2002;  347 408-415
    CrossrefPubMedGoogle Scholar
  • 49 Singh N, Limaye A P, Forrest G. et al . Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study.  Transplantation. 2006;  81 320-326
    CrossrefPubMedGoogle Scholar
  • 50 Pfaller M A, Diekema D J, Jones R N. et al . Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000.  J Clin Microbiol. 2002;  40 852-856
    CrossrefPubMedGoogle Scholar
  • 51 Pfaller M A, Messer S A, Hollis R J, Jones R N. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and Amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.  Antimicrob Agents Chemother. 2002;  46 1032-1037
    CrossrefPubMedGoogle Scholar

PD Markus Weigand

Klinik für Anaesthesiologie
Universität Heidelberg

Im Neuenheimer Feld 110
69120 Heidelberg

Phone: 06221/56-36162

Fax: 06221/56-5345

Email: markus.weigand@med.uni-heidelberg.de

      >